While clinical trials for these targeted therapies are still ongoing, inhibition of this pathway along with standardized evaluation of HGF and c-Met expression profiles with clinical outcomes is warranted in order to provide certain HNSCC patients another viable treatment strategy. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.